Tuan Nguyen - 31 Mar 2025 Form 4/A - Amendment Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Financial Officer
Signature
/s/ David Kille as attorney-in-fact for Tuan Nguyen
Issuer symbol
ABUS
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
01 Apr 2025, 17:47:47 UTC
Date Of Original Report
31 Mar 2025
Previous filing
31 Mar 2025
Next filing
02 Feb 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +750,000 $0.000000 750,000 31 Mar 2025 Common Shares 750,000 $3.49 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2 This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

This amendment on Form 4/A is being filed solely to correct the exercise price of the stock option, which was incorrectly reported on the original Form 4 filed by the Reporting Person on March 31, 2025.